{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03720613",
            "orgStudyIdInfo": {
                "id": "1711V9241"
            },
            "organization": {
                "fullName": "BioDelivery Sciences International",
                "class": "INDUSTRY"
            },
            "briefTitle": "Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain",
            "officialTitle": "Risk of Major Adverse Cardiovascular Events Among Users of Naldemedine Compared With Other Medications Used for Opioid Induced Constipation in Adult Patients With Chronic Non-Cancer Pain in a Healthcare Claims Database",
            "therapeuticArea": [
                "Other"
            ],
            "study": "risk-of-major-adverse-cardiovascular-events-for-naldemedine-and-other-medications-for-opioid-induced-constipation-in-adults-with-chronic-non-cancer-pain"
        },
        "statusModule": {
            "statusVerifiedDate": "2022-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-01-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2030-11-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-11-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-10-24",
            "studyFirstSubmitQcDate": "2018-10-24",
            "studyFirstPostDateStruct": {
                "date": "2018-10-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2022-02-28",
            "lastUpdatePostDateStruct": {
                "date": "2022-03-02",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BioDelivery Sciences International",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "HealthCore, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced constipation (OIC) medications."
        },
        "conditionsModule": {
            "conditions": [
                "Opioid-induced Constipation"
            ],
            "keywords": [
                "naloxegol",
                "major adverse cardiovascular event (MACE)",
                "opioid induced constipation (OIC)",
                "lubiprostone",
                "naldemedine"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 34532,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Naldemedine",
                    "description": "Patients with chronic non-cancer pain who initiated naldemedine treatment for opioid-induced constipation.",
                    "interventionNames": [
                        "Drug: Naldemedine"
                    ]
                },
                {
                    "label": "Lubiprostone",
                    "description": "Patients with chronic non-cancer pain who initiated lubiprostone treatment for opioid-induced constipation.",
                    "interventionNames": [
                        "Drug: Lubiprostone"
                    ]
                },
                {
                    "label": "Naloxegol",
                    "description": "Patients with chronic non-cancer pain who initiated naloxegol treatment for opioid-induced constipation.",
                    "interventionNames": [
                        "Drug: Naloxegol"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Naldemedine",
                    "description": "0.2 mg tablet once a day at any time with or without food",
                    "armGroupLabels": [
                        "Naldemedine"
                    ],
                    "otherNames": [
                        "Symproic\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Lubiprostone",
                    "description": "0.024 mg twice a day \\[adjust dose based on liver function\\]",
                    "armGroupLabels": [
                        "Lubiprostone"
                    ],
                    "otherNames": [
                        "Amitiza\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Naloxegol",
                    "description": "25 mg tablet once a day in morning, 1 hour before or 2 hours after food",
                    "armGroupLabels": [
                        "Naloxegol"
                    ],
                    "otherNames": [
                        "Movantik\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with a Major Adverse Cardiovascular Event",
                    "description": "A composite of major adverse cardiovascular events, cardiovascular (CV) death, nonfatal myocardial infarction (MI), and non-fatal stroke.",
                    "timeFrame": "5 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of Participants with Cardiovascular Death",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Number of Participants with Nonfatal Myocardial Infarction",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Number of Participants with Nonfatal Stroke",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* At least one dispensing of naldemedine or lubiprostone or naloxegol without prior use in the database of either medication (index date)\n* At least two dispensings of opioids within six months prior to and including the index date, with at least a combined 31 cumulative days supply\n* At least 18 years of age or older on the index date\n* At least six months of continuous health plan coverage that includes medical and pharmacy benefits prior to and including the index date\n\nExclusion Criteria:\n\n* Any acute MACE (non-fatal MI or non-fatal stroke) within six months before or on the index date\n* Any cancer treatment or cancer pain diagnosis within six months before or on the index date\n* Prior use of methylnaltrexone, alvimopan or naloxegol within six months before or on the index date",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "The study population will include new users of naldemedine or one of the comparator OIC medications (lubiprostone or naloxegol) who satisfy all of the inclusion criteria and none of the exclusion criteria.",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Todd Kunkel",
                    "role": "CONTACT",
                    "phone": "913-940-1789",
                    "email": "tkunkel@bdsi.com"
                },
                {
                    "name": "Tom Smith",
                    "role": "CONTACT",
                    "email": "tsmith@bdsi.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Stephen Lanes",
                    "affiliation": "HealthCore, Inc.",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Wilmington",
                    "state": "Delaware",
                    "zip": "19801",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.74595,
                        "lon": -75.54659
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003248",
                    "term": "Constipation"
                },
                {
                    "id": "D000079689",
                    "term": "Opioid-Induced Constipation"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012817",
                    "term": "Signs and Symptoms, Digestive"
                },
                {
                    "id": "D000079524",
                    "term": "Narcotic-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6472",
                    "name": "Constipation",
                    "asFound": "Constipation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M2075",
                    "name": "Opioid-Induced Constipation",
                    "asFound": "Opioid-Induced Constipation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15622",
                    "name": "Signs and Symptoms, Digestive",
                    "relevance": "LOW"
                },
                {
                    "id": "M2057",
                    "name": "Narcotic-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000589308",
                    "term": "Naloxegol"
                },
                {
                    "id": "D000068238",
                    "term": "Lubiprostone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000065101",
                    "term": "Chloride Channel Agonists"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000009292",
                    "term": "Narcotic Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                },
                {
                    "id": "M230640",
                    "name": "Naloxegol",
                    "asFound": "Clinical protocol",
                    "relevance": "HIGH"
                },
                {
                    "id": "M239",
                    "name": "Lubiprostone",
                    "asFound": "Manometry",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12243",
                    "name": "Narcotic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "T217",
                    "name": "Mace",
                    "relevance": "LOW"
                },
                {
                    "id": "T240",
                    "name": "Nutmeg",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                },
                {
                    "abbrev": "HB",
                    "name": "Herbal and Botanical"
                }
            ]
        }
    },
    "hasResults": false
}